Achieve Life Sciences (ACHV) vs QuidelOrtho (QDEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed QuidelOrtho (QDEL) over the past year, gaining 108.4% versus a loss of 55.5%. Over five years, ACHV leads with a -10.7% price change compared with -90.3% for QDEL. QuidelOrtho is the larger company by market cap ($851.0 million vs $741.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | QDEL |
|---|---|---|
| Share price | $7.19 | $12.41 |
| Market cap | $741.31M | $851.02M |
| 1-day change | -0.69% | +0.81% |
| YTD return | +44.67% | -56.55% |
| 1-year return | +108.41% | -55.46% |
| 5-year return | -10.68% | -90.32% |
| Forward P/E | — | 8.61 |
| EPS (TTM) | $-1.69 | $-15.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.64 | $35.58 |
| 52-week low | $2.62 | $9.92 |
| Distance from 52-week high | -16.78% | -65.12% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +96.80% | +18.21% |
| Average volume | 1.43M | 1.51M |
| Shares outstanding | 103.10M | 68.58M |
| Employees | 28 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACHV has outperformed QDEL by 163.9 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
ACHV vs QDEL FAQ
Which is bigger, Achieve Life Sciences or QuidelOrtho?
QuidelOrtho (QDEL) is larger, with a market capitalization of $851.02M compared with $741.31M for Achieve Life Sciences (ACHV).
Which stock has performed better over the past year, ACHV or QDEL?
ACHV returned +108.41% over the past 12 months, compared with -55.46% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and QuidelOrtho in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.